The DOI matches its Crossref record; 316 of the 322 references it cites were found in a registry or an index.
Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies
Open accessAbstract
Reprogramming of glucose metabolism provides sufficient energy and raw materials for the proliferation, metastasis, and immune escape of cancer cells, which is enabled by glucose metabolism-related enzymes that are abundantly expressed in a broad range of cancers. Therefore, targeting glucose metabolism enzymes has emerged as a promising strategy for anticancer drug development. Although several glucose metabolism modulators have been approved for cancer treatment in recent years, some limitations exist, such as a short half-life, poor solubility, and numerous adverse effects. With the rapid development of medicinal chemicals, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies have found that some natural products can suppress cancer progression by regulating glucose metabolism enzymes. In this review, we summarize the mechanisms underlying the reprogramming of glucose metabolism and present enzymes that could serve as therapeutic targets. In addition, we systematically review the existing drugs targeting glucose metabolism enzymes, including small-molecule modulators and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeted anticancer drugs are also discussed. In conclusion, combining glucose metabolism modulators with conventional anticancer drugs may be a promising cancer treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While many of these have shown efficacy in pre-clinical models, challenges in achieving selectivity, combined with pathway redundancies and bypass mechanisms may limit their utility as single agents in the clinic [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, anti-cancer agents that target the multiple steps of glucose metabolism from glucose uptake to lactate production have also been developed (Table 2) [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“For most malignant tumors, angiogenesis, a hallmark of cancer, is not only a significant feature but also a drug target [74].”
BackgroundTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 4×
“In the 1920s, Otto Warburg first observed that cancer cells tend to metabolize glucose to lactate even in the presence of sufficient oxygen, known as the Warburg effect or aerobic glycolysis (Figure 1B) [2].”
BackgroundInfluentialThe Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“Although the energy produced by each glucose molecule during aerobic glycolysis is less than that produced by OXPHOS, aerobic glycolysis can generate a number of ATP molecules comparable to OXPHOS when the amount of glucose is sufficient [16].”
BackgroundMetabolic regulation of gene expression by histone lactylation
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1678-1 · Cited by 4,371 · cited 1×
“Lactate participates in the homeostatic regulation of M1 macrophages [20] and inhibits CD8+ T cells and natural killer cells (NK cells) from producing γ-interferon [21], which in turn maintains an immunosuppressive microenvironment [22,23].”
BackgroundA guide to immunometabolism for immunologists
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.70 · Cited by 3,315
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057 · cited 1×
“Oxidative phosphorylation (OXPHOS) and anaerobic glycolysis are the two major catabolic glucose pathways, in which glycolysis is the common initiation pathway of both [1].”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740 · cited 1×
“Extensive studies have confirmed that metabolic reprogramming of glucose, which plays a vital role in the proliferation, invasion and metastasis of cancer cells, is closely associated with the survival of cancer cells [24,25].”
BackgroundOne-Carbon Metabolism in Health and Disease
Ducker, G. S., & Rabinowitz, J. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.009 · Cited by 2,239 · cited 3×
“For example, glucose-6-phosphate (G-6-P) is a substrate for the pentose phosphate pathway that produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate (R-5-P) substrates, and R-5-P is a substrate for nucleic acid synthesis.”
BackgroundYang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“By inhibiting glucose transporters, specifically GLUT1, which is often overexpressed in various cancers, these inhibitors effectively starve cancer cells of their primary energy source [60, 216].”
BackgroundUnveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Further reports suggest the resistance dependence of cancer cells on glycolytic intermediate and glucose transporter are therapeutically significant nodes in both preclinical and clinical settings [292].”
BackgroundModulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
“Additionally, several of the glycolysis inhibitors that have been developed for clinical use have been shown to have off-target effects, killing non-cancerous cells [327].”
BackgroundWang, Z., Zhang, X., Fang, C., Liu, X., Liao, Q., Wu, N., & Wang, J. (2024) · Immunology · doi:10.1111/imm.13793 · Cited by 204
“As a result, inhibiting glucose metabolism enzymes has shown great promise as a novel cancer treatment strategy [140 – 142].”
Lu, H., Tong, W., Jiang, M., Liu, H., Meng, C., Wang, K., & Mu, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c04024 · Cited by 105
Metadata
- Authors
- Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B.
- Affiliations
- Sichuan University (CN)
- Monash University (AU)
- Weifang Medical University (CN)
- Corresponding author
- Wei, Liuya
- Zou, Bingwen
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-21
- Volume
- 14
- Issue
- 19
- Pages
- 4568
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9559313
- OpenAlex
- W4296991129
- Cited by
- 144
- References
- 322
- Citations by year
- 2026: 21 · 2025: 54 · 2024: 40 · 2023: 28 · 2022: 1
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Clinical Research Incubation Project, West China Hospital, Sichuan University (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Science and Technology Department of Sichuan Province (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Beijing Medical Award Foundation (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- 1·3·5 project for disciplines of excellence (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- National Natural Science Foundation of China (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glucose metabolism reprogramming, glucose metabolism enzymes, cancer metabolism, anticancer drug development, metabolic therapy, natural products, small molecule modulators, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. https://app.cochat.ai/papers/10.3390/cancers14194568
- The paper
- Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022). Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers. https://doi.org/10.3390/cancers14194568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.